<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty patients of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were treated over a period of 2 yr using 3 different treatment regimens </plain></SENT>
<SENT sid="1" pm="."><plain>Twelve patients received <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>, 4 were given low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> and 14 others were treated with an aggressive <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) induction regimen </plain></SENT>
<SENT sid="2" pm="."><plain>A low complete remission was obtained in the first 2 groups (17 and 25% respectively), whereas 9 (64%) patients attained complete remission with the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> induction regimen </plain></SENT>
<SENT sid="3" pm="."><plain>Remission in the latter group was associated with prolonged and severe <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> requiring intensive support </plain></SENT>
<SENT sid="4" pm="."><plain>Patients in <z:hpo ids='HP_0000001'>all</z:hpo> the 3 groups had a short duration of remission culminating in <z:hpo ids='HP_0011420'>death</z:hpo> with progressive marrow failure or evolution to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, indicating the limitations of the current treatment strategies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and highlighting the need for exploring newer therapeutic approaches </plain></SENT>
</text></document>